UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 7.960

Sortiert nach

26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB120-AB120

2021

Link zum Volltext

Verfügbarkeit prüfen

Patterns of sensitization to inhalant allergens, Ole e 1 and Ole e 7 in children and adolescents born in the same area with different origin

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB129

2020

Link zum Volltext

Verfügbarkeit prüfen

26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB97-AB97

2021

Link zum Volltext

Verfügbarkeit prüfen

S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S327-S327

2020

Link zum Volltext

Verfügbarkeit prüfen

P90: LANADELUMAB EFFICACY AND SAFETY REGARDLESS OF BASELINE ATTACK RATE IN PATIENTS WITH PREVIOUS LONG‐TERM PROPHYLAXIS OF HEREDITARY ANGIOEDEMA: A POST HOC SUBANALYSIS OF HELP OLE

Internal medicine journal, 2022-10, Vol.52, p.27-28

2022

Link zum Volltext

Verfügbarkeit prüfen

New insights into the sensitization to nonspecific lipid transfer proteins from pollen and food: New role of allergen Ole e 7

Allergy (Copenhagen), 2020-04, Vol.75 (4), p.798-807

2020

Link zum Volltext

Verfügbarkeit prüfen

Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open‐Label Extension (OLE)

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

34367 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB106-AB106

2022

Link zum Volltext

Verfügbarkeit prüfen

34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB180-AB180

2022

Link zum Volltext

Verfügbarkeit prüfen

Needs for a thorough Joint Clinical Assessment of vaccines within the HTAR: perspectives of NITAGs: Ole Wichmann

European journal of public health, 2022-10, Vol.32 (Suppl 3)

Wichmann, O

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial

Journal of allergy and clinical immunology, 2022-02, Vol.149 (2), p.AB10-AB10

2022

Link zum Volltext

Verfügbarkeit prüfen

Lanadelumab efficacy and safety after switching from androgens: analysis of the phase 3 HELP and HELP OLE studies for hereditary angioedema

Journal of allergy and clinical immunology, 2022-02, Vol.149 (2), p.AB166-AB166

2022

Link zum Volltext

Verfügbarkeit prüfen

P054 ATTACK-FREE STATUS IN THE HELP OLE: LONG-TERM LANADELUMAB PROPHYLACTIC TREATMENT FOR 12 MONTHS OR LONGER

Annals of allergy, asthma, & immunology, 2021-11, Vol.127 (5), p.S29

2021

Link zum Volltext

Verfügbarkeit prüfen

DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i110-i111

2023

Link zum Volltext

Verfügbarkeit prüfen

27419 Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB142-AB142

2021

Link zum Volltext

Verfügbarkeit prüfen

27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB143-AB143

2021

Link zum Volltext

Verfügbarkeit prüfen

Attack-Free Status of Patients With Hereditary Angioedema (HAE) During Extended Treatment With Lanadelumab in the HELP OLE Study

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB104

2020

Link zum Volltext

Verfügbarkeit prüfen

Pru p 9 and Ole e 6-like, two new Peach tree pollen allergens, can elicit respiratory symptoms in children

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB72

2020

Link zum Volltext

Verfügbarkeit prüfen

Influence of OTC on OLE for college students: mediating effect of academic emotion and moderating effect of gender

Current psychology (New Brunswick, N.J.), 2023-04, Vol.43 (5), p.3973-3986

2023

Link zum Volltext

Verfügbarkeit prüfen

Remembering the Good Ole Days: Fear of Positive Emotion Relates to Affect Repair Using Positive Memories

Cognitive therapy and research, 2017-06, Vol.41 (3), p.362-368

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)

Journal of allergy and clinical immunology, 2021-02, Vol.147 (2), p.AB24-AB24

2021

Link zum Volltext

Verfügbarkeit prüfen

P157 ATTACK-FREE STATUS DURING EXTENDED TREATMENT WITH LANADELUMAB FOR HEREDITARY ANGIOEDEMA: HELP OLE STUDY FINAL RESULTS

Annals of allergy, asthma, & immunology, 2020-11, Vol.125 (5), p.S23-S23

2020

Link zum Volltext

Verfügbarkeit prüfen

15108 Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB141-AB141

2020

Link zum Volltext

Verfügbarkeit prüfen

16292 Dupilumab treatment for up to 3 years demonstrates sustained efficacy in adult patients with moderate to severe atopic dermatitis: Results from LIBERTY AD Adult OLE

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB175-AB175

2020

Link zum Volltext

Verfügbarkeit prüfen

Increased Response to Higher Dose Lanadelumab in Hereditary Angioedema Patients: Exploratory Findings From the HELP and HELP OLE Studies

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB38-AB38

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 7.960

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Ovid Full Text

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(7.659)
Mit Volltextzugriff
(6.888)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(1.121)
Social Sciences
(714)
Male
(682)
Biological And Medical Sciences
(677)
Female
(615)
Medical Sciences
(498)
Animals
(479)
Adult
(396)
Middle Aged
(336)
Psychology
(284)
Fundamental And Applied Biological Sciences. Psychology
(240)
Aged
(226)
Studies
(181)
Education
(175)
Rats
(154)
Adolescent
(142)
Business & Economics
(142)
Social Sciences - Other Topics
(141)
Risk Factors
(126)
Philosophy
(121)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Lancet
(158)
Nature
(122)
The American Journal Of Gastroenterology
(86)
Diabetes
(85)
Alzheimer's & Dementia
(80)
Nordic Journal Of Psychiatry
(79)
Thrombosis And Haemostasis
(78)
Acta Obstetricia Et Gynecologica Scandinavica
(66)
Journal Of Clinical Oncology
(65)
Psicothema
(63)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)

Patterns of sensitization to inhalant allergens, Ole e 1 and Ole e 7 in children and adolescents born in the same area with different origin

26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)

S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE

P90: LANADELUMAB EFFICACY AND SAFETY REGARDLESS OF BASELINE ATTACK RATE IN PATIENTS WITH PREVIOUS LONG‐TERM PROPHYLAXIS OF HEREDITARY ANGIOEDEMA: A POST HOC SUBANALYSIS OF HELP OLE

New insights into the sensitization to nonspecific lipid transfer proteins from pollen and food: New role of allergen Ole e 7

Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open‐Label Extension (OLE)

34367 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years

34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years

Needs for a thorough Joint Clinical Assessment of vaccines within the HTAR: perspectives of NITAGs: Ole Wichmann

Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial

Lanadelumab efficacy and safety after switching from androgens: analysis of the phase 3 HELP and HELP OLE studies for hereditary angioedema

P054 ATTACK-FREE STATUS IN THE HELP OLE: LONG-TERM LANADELUMAB PROPHYLACTIC TREATMENT FOR 12 MONTHS OR LONGER

DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients

27419 Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study

27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study

Attack-Free Status of Patients With Hereditary Angioedema (HAE) During Extended Treatment With Lanadelumab in the HELP OLE Study

Pru p 9 and Ole e 6-like, two new Peach tree pollen allergens, can elicit respiratory symptoms in children

Influence of OTC on OLE for college students: mediating effect of academic emotion and moderating effect of gender

Remembering the Good Ole Days: Fear of Positive Emotion Relates to Affect Repair Using Positive Memories

Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)

P157 ATTACK-FREE STATUS DURING EXTENDED TREATMENT WITH LANADELUMAB FOR HEREDITARY ANGIOEDEMA: HELP OLE STUDY FINAL RESULTS

15108 Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)

16292 Dupilumab treatment for up to 3 years demonstrates sustained efficacy in adult patients with moderate to severe atopic dermatitis: Results from LIBERTY AD Adult OLE

Increased Response to Higher Dose Lanadelumab in Hereditary Angioedema Patients: Exploratory Findings From the HELP and HELP OLE Studies

Aktive Filter

Suchergebnisse filtern